Empowered Patient Podcast

Making Whole Exome Sequencing Affordable Accessible Interpretable with Dahlia Attia-King Panacea

Informações:

Synopsis

Dahlia Attia-King, CEO of Panacea, is bringing whole exome sequencing to a broader audience and promoting the value of this data for disease prevention and making smarter lifestyle choices. She highlights the differences between whole exome sequencing and whole genome sequencing, noting that whole exome sequencing can be conducted more cost-effectively and provide information about the genes most likely to impact health.   Dahlia explains, "These two barriers, the physicians and the insurers, are sometimes big barriers to accessing clinical genetic testing for people, even those who need it and those who fit the current guidelines. We aim to bypass those barriers and partner with very skilled CLIA/CAP certified laboratories. We partner with trained clinical genetic counselors. We partner with physicians who understand how to utilize genetic testing, and we bring those services collectively in one very simple, user-friendly experience so that no one who wants genetic testing will struggle to get it." "We do